Patents-Review.com
🔗 Permalink
Assignee profile:

AMAL THERAPEUTICS SA

City:

Geneva

Country:

Switzerland

Published Applications:

12

Last publication date:

2022-09-29

Patent Grants:

6

Last grant date:

2025-02-11

Top Inventors for applications by AMAL THERAPEUTICS SA

These are the the leading inventors for applications assigned to AMAL THERAPEUTICS SA:

Recent patent applications by AMAL THERAPEUTICS SA

AMAL THERAPEUTICS SA based in Geneva, CH has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2022-09-29 ✅ Patent 12,220,387 granted on 2025-02-11
US20220305101A1
Human necessities

Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer

 #2 | 2022-06-09 ✅ Patent 12,453,762 granted on 2025-10-28
US20220175933A1
Human necessities

Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma

 #3 | 2022-04-21 ✅ Patent 12,214,048 granted on 2025-02-04
US20220118102A1
Human necessities

Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine

 #4 | 2022-02-10 ✅ Patent 12,178,788 granted on 2024-12-31
US20220040314A1
Human necessities

Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist

 #5 | 2022-02-03 ✅ Patent 12,220,450 granted on 2025-02-11
US20220031850A1
Human necessities

Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer

 #6 | 2021-03-25 ✅ Patent 11,338,027 granted on 2022-05-24
US20210085768A1
Human necessities

Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer

 #7 | 2019-08-22
US20190255165A1
Human necessities

Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer

 #8 | 2019-06-13
US20190175748A1
Human necessities

COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE

 #9 | 2018-05-17
US20180133339A1
Human necessities

A Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma

 #10 | 2018-05-17
US20180133338A1
Human necessities

A Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer

 #11 | 2018-05-17
US20180133327A1
Human necessities

Cell Penetrating Peptides and Complexes Comprising the Same

 #12 | 2018-05-17
US20180133295A1
Human necessities

A Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist

Also check out Amal Therapeutics SA's (Geneva, Switzerland) applicant profile with 6 patent applications submitted.

AssigneeID:

135035 ⎘